a Department of Urology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China b Department of Urology, Baoji Center Hospital, Baoji, China c Department of Pathology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
Objective: To assess the concordance of tumour grade in specimens obtained from diagnostic cystoscopic biopsy and transurethral resection of bladder tumour (TURBT) and explore the risk factors of upgrading.
Methods: The medical records of 205 outpatients who underwent diagnostic cystoscopic biopsy before initial TURBT were retrospectively reviewed. Comparative analysis of the tumour grade of biopsy and operation specimens was performed. Tumour grade changing from low-grade to high-grade with or without variant histology was defined as upgrading. Logistic regression analyses were performed to identify the risk factors of upgrading.
Results: For the 205 patients, the concordance of tumour grade between specimens obtained from biopsy and operation was 0.639. The concordance for patients who were preoperatively diagnosed with low-grade and high-grade was 0.504 and 0.912, respectively. Univariate and multivariate logistic regression analyses showed that older age, tumour multifocality, high neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and low lymphocyte-to-monocyte ratio (LMR) were significantly associated with upgrading (odds ratio ranging from 0.412 to 4.364). The area under the curve of the different multivariate models was improved from 0.752 to 0.821, and decision curve analysis demonstrated a high net benefit when NLR, LMR, and PLR were added.
Conclusion: Diagnostic cystoscopic biopsy may not accurately represent the true grade of primary bladder cancer, especially for outpatients with low-grade bladder cancer. Moreover, older age, tumour multifocality, high NLR, PLR, and low LMR are risk factors of upgrading, and systemic inflammatory markers improve the predictive ability.
. [J]. Asian Journal of Urology, 2023, 10(1): 19-26.
Junjie Fan,Hua Liang,Jinhai Fan,Lei Li,Guanjun Zhang,Xinqi Pei,Tao Yang,Dalin He,Kaijie Wu. Diagnostic accuracy of cystoscopic biopsy for tumour grade in outpatients with urothelial carcinoma of the bladder and the risk factors of upgrading. Asian Journal of Urology, 2023, 10(1): 19-26.
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017; 71:96e108.
doi: S0302-2838(16)30280-9
pmid: 27370177
Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk super?cial bladder tumors. J Urol 1988; 139:283e5.
doi: 10.1016/S0022-5347(17)42387-1
[4]
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 2016; 196:1021e9.
doi: 10.1016/j.juro.2016.06.049
pmid: 27317986
[5]
Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classi?cation system. Pathol Int 2010; 60:1e8.
doi: 10.1111/j.1440-1827.2009.02477.x
pmid: 20055945
[6]
Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66(6 Suppl 1):4e34.
[7]
Iida S, Kondo T, Kobayashi H, Hashimoto Y, Goya N, Tanabe K. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience. Int J Urol 2009; 16:287e92.
doi: 10.1111/j.1442-2042.2008.02239.x
pmid: 19207115
[8]
Nishiyama N, Kitamura H, Maeda T, Takahashi S, Masumori N, Hasegawa T, et al. Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classi?cation system. Jpn J Clin Oncol 2013; 43:1124e31.
doi: 10.1093/jjco/hyt120
pmid: 23980236
[9]
Babjuk M, Burger M, Comperat EM, Gontero P, Mosta?d AH, Palou J, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)d2019 update. Eur Urol 2019 ; 76:639e57.
doi: S0302-2838(19)30660-8
pmid: 31443960
[10]
Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int 2008; 102(9 Pt B):1242e6.
[11]
Li K, Lin T; Chinese Bladder Cancer Consortium; Xue W, Mu X, Xu E, et al. Current status of diagnosis and treatment of bladder cancer in Chinadanalyses of Chinese Bladder Cancer Consortium database. Asian J Urol 2015; 2:63e9.
[12]
Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG. Cancer heterogeneity and its biologic implica-tions in the grading of urothelial carcinoma. Cancer 2000; 88: 1663e70.
pmid: 10738225
[13]
Billis A, Carvalho RB, Mattos AC, Negretti F, Nogueira CR, Oliveira MC, et al. Tumor grade heterogeneity in urothelial bladder carcinomadproposal of a system using combined numbers. Scand J Urol Nephrol 2001; 35:275e9.
pmid: 11676351
[14]
Bircan S, Candir O, Serel TA. Comparison of WHO Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma. Urol Int 2004; 73:201e8.
doi: 10.1159/000080828
[15]
Warrick JI, Sjodahl G, Kaag M, Raman JD, Merrill S, Shuman L, et al. Intratumoral heterogeneity of bladder cancer by mo-lecular subtypes and histologic variants. Eur Urol 2019; 75: 18e22.
doi: S0302-2838(18)30653-5
pmid: 30266310
[16]
Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hansel DE, et al. Update for the practicing pathologist: the International Consultation on Urologic Disease-European as-sociation of urology consultation on bladder cancer. Mod Pathol 2015; 28:612e30.
doi: 10.1038/modpathol.2014.158
[17]
Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 2010; 105:300e8.
doi: 10.1111/j.1464-410X.2009.09076.x
pmid: 19912200
[18]
Benson Jr RC, Tomera KM, Kelalis PP. Transitional cell carci-noma of the bladder in children and adolescents. J Urol 1983; 130:54e5.
doi: 10.1016/s0022-5347(17)50950-7
pmid: 6864914
[19]
Linn JF, Sesterhenn I, Mosto? FK, Schoenberg M. The molec-ular characteristics of bladder cancer in young patients. J Urol 1998; 159:1493e6.
doi: 10.1097/00005392-199805000-00022
pmid: 9554340
[20]
Janisch F, Yu H, Vetterlein MW, Dahlem R, Engel O, Fisch M, et al. Do younger patients with muscle-invasive bladder can-cer have better outcomes? J Clin Med 2019; 8:1459. https: //doi.org/10.3390/jcm8091459.
doi: 10.3390/jcm8091459
[21]
Shapur N, Pode D, Katz R, Shapiro A, Yutkin V, Pizov G, et al. Predicting the risk of high-grade bladder cancer using nonin-vasive data. Urol Int 2011; 87:319e24.
doi: 10.1159/000328635
[22]
Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, et al. Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors. Eur Urol 2019; 76:200e6.
doi: S0302-2838(19)30352-5
pmid: 31092337
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883e99.
doi: 10.1016/j.cell.2010.01.025
pmid: 20303878
[27]
Tang X, Wang S, An C, Du P, Yang Y. Preoperative high neutrophil-to-lymphocyte ratio is associated with high-grade bladder cancer. Anticancer Res 2017; 37:4659e63.
pmid: 28739768
[28]
Rajwa P, Zyczkowski M, Paradysz A, Bujak K, Bryniarski P. Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cys-tectomy. Eur Rev Med Pharmacol Sci 2018; 22:3027e37.
[29]
Azab B, Camacho-Rivera M, Taioli E. Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects. PloS One 2014; 9:e112361. https://doi.org/10.1371/journal.pone.0112361.
doi: 10.1371/journal.pone.0112361
